Keyphrases
Melanoma
71%
Metastatic Melanoma
66%
Overall Survival
30%
Clinical Outcomes
27%
Absolute Lymphocyte Count
26%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Immune Checkpoint Inhibitors
21%
Progression-free Survival
20%
Tumor
18%
Melanoma Patients
17%
Non-Hodgkin Lymphoma
17%
Natural Killer Cells
15%
T Cells
15%
Malignant Melanoma
14%
Mayo Clinic
13%
Advanced Melanoma
13%
Autologous Peripheral Hematopoietic Stem Cell Transplantation
13%
Interferon-α (IFN-α)
13%
Chemotherapy
13%
Peripheral Blood
13%
Diffuse Large B-cell Lymphoma (DLBCL)
13%
Confidence Interval
13%
Granulocyte Colony-stimulating Factor (G-CSF)
12%
Bevacizumab
12%
Stage IV Melanoma
12%
Autograft
11%
Hazard Ratio
11%
Lymphocytes
11%
Programmed Death-ligand 1 (PD-L1)
11%
Ipilimumab
11%
Lymphocyte-to-monocyte Ratio
11%
Clinical Trials
10%
Phase II Trial
9%
Lymphoma
9%
Immune Response
9%
Median Overall Survival
9%
Paclitaxel
9%
Cancer Immunotherapy
9%
Carboplatin
9%
Phase II Study
9%
Lymphocyte Recovery
8%
Monocytes
8%
Immune System
8%
Nab-paclitaxel
8%
Rituximab
8%
Cancer Treatment
7%
In Cancer
7%
Extracellular Vesicles
7%
Autograft Absolute Lymphocyte Count
7%
Prognostic Factors
7%
Medicine and Dentistry
Melanoma
100%
Lymphocyte
36%
Metastatic Melanoma
36%
Overall Survival
30%
Diseases
28%
Neoplasm
23%
Immune Checkpoint Inhibitor
19%
Progression Free Survival
19%
Immunotherapy
14%
Diffuse Large B-Cell Lymphoma
13%
Malignant Neoplasm
13%
Autologous Stem Cell Transplantation
12%
Metastatic Carcinoma
12%
Clinical Trial
12%
Non-Hodgkin Lymphoma
10%
T Cell
10%
Cytokine
9%
Brain Metastasis
9%
Autograft
9%
Hematopoietic Stem Cell Transplantation
8%
Recurrent Disease
8%
Hazard Ratio
8%
Natural Killer Cell
8%
Cytotoxic T-Cell
7%
Prognostic Factor
7%
Cancer
7%
Biological Marker
7%
Cancer Immunotherapy
7%
Granulocyte Macrophage Colony Stimulating Factor
6%
Radiation Therapy
6%
Paclitaxel
6%
Cancer Therapy
5%
Immune System
5%
Adverse Event
5%
Arm
5%
Lymph Node
5%
Meta-Analysis
5%
Everolimus
5%
Bevacizumab
5%
Melanoma Skin Cancer
5%
Survival Rate
5%
Multivariate Analysis
5%
Pembrolizumab
5%